VRTX VERTEX PHARMACEUTICALS INC / MA
Pharmaceutical Preparations · Nasdaq · SEC CIK 875320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.5%
TTM net income YoY8.2%
TTM EPS YoY9.4%
Revenue 3-yr CAGR10.3%
Net income 3-yr CAGR4.6%
Margins
Gross margin85.5%
Operating margin33.2%
Net margin30.7%
FCF margin24.7%
EBITDA margin35.1%
Returns
ROE20.8%
ROA13.8%
ROIC (approx.)21.9%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets36.1%
Debt / equity0.22x
Current ratio2.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio1.0%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.44B | $3.33B | $2.99B | $3.19B | $3.08B | $2.96B | $2.77B | $2.91B |
| Cost of revenue | $526.10M | $489.20M | $392.80M | $466.00M | $414.80M | $407.50M | $363.00M | $423.40M |
| Gross profit | $2.91B | $2.84B | $2.59B | $2.72B | $2.66B | $2.56B | $2.41B | $2.49B |
| R&D expense | $1.32B | $993.80M | $961.60M | $973.70M | $977.70M | $978.40M | $979.70M | $998.70M |
| SG&A expense | $844.10M | $582.20M | $493.70M | $487.00M | $445.10M | $424.60M | $396.40M | $377.60M |
| Operating income | $712.90M | $1.25B | $1.14B | $1.21B | $1.19B | $1.15B | $630.10M | $1.03B |
| Interest expense | $36.00M | — | — | $3.30M | $3.30M | $3.70M | $3.00M | $2.80M |
| Pretax income | $783.40M | $1.39B | $1.25B | $1.33B | $1.30B | $1.28B | $730.40M | $1.14B |
| Income tax | $129.80M | $292.00M | $221.50M | $139.90M | $215.90M | $250.10M | $84.10M | $223.50M |
| Net income | $653.60M | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B | $646.30M | $913.00M |
| EBITDA | $782.10M | $1.30B | $1.19B | $1.26B | $1.24B | $1.20B | $678.50M | $1.07B |
| EPS (basic) | 2.58 | 4.34 | 4.06 | — | 4.24 | 4.02 | 2.52 | — |
| EPS (diluted) | 2.56 | 4.31 | 4.02 | — | 4.20 | 3.99 | 2.49 | — |
| Weighted avg. shares (diluted) | 255.20M | 255.20M | 256.30M | — | 257.60M | 258.90M | 259.50M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.98B | $6.14B | $5.49B | $5.08B | $4.94B | $4.97B | $4.67B | $4.57B |
| Short-term investments | $1.32B | $1.71B | $1.75B | $1.52B | $1.35B | $1.41B | $1.53B | $1.55B |
| Receivables | $2.31B | $2.13B | $2.00B | $2.05B | $1.95B | $1.89B | $1.81B | $1.61B |
| Inventory | $2.25B | $1.77B | $1.77B | $1.69B | $1.63B | $1.50B | $1.36B | $1.21B |
| Current assets | $11.69B | $12.54B | $11.73B | $11.20B | $10.57B | $10.43B | $10.01B | $9.60B |
| PP&E, net | $1.71B | $1.67B | $1.61B | $1.52B | $1.43B | $1.34B | $1.30B | $1.23B |
| Goodwill | $2.42B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B |
| Intangibles | $8.52B | $412.80M | $418.50M | $424.20M | $429.80M | $435.50M | $441.20M | $825.90M |
| Total assets | $32.74B | $27.42B | $26.48B | $25.64B | $24.86B | $24.04B | $22.88B | $22.53B |
| Current liabilities | $5.00B | $3.94B | $3.88B | $3.86B | $4.48B | $4.14B | $3.78B | $3.56B |
| Short-term debt | $999.60M | — | — | $0 | — | — | — | — |
| Long-term debt | $3.50B | — | — | $0 | — | — | — | — |
| Total debt | $4.50B | — | — | $0 | — | — | — | — |
| Total liabilities | $11.83B | $7.18B | $7.12B | $6.98B | $7.54B | $6.86B | $6.38B | $6.12B |
| Shareholders' equity | $20.91B | $20.25B | $19.36B | $18.67B | $17.32B | $17.18B | $16.50B | $16.41B |
| Net debt | -$482.70M | — | — | -$5.08B | — | — | — | — |
| Shares outstanding | 253.52M | 253.35M | 254.16M | 253.99M | 253.95M | 256.29M | 256.97M | 256.94M |
| Cash flow statement | ||||||||
| Operating cash flow | $643.10M | $1.13B | $1.43B | $498.00M | $1.24B | $1.07B | $818.90M | $584.60M |
| Capital expenditure | $97.30M | $112.20M | $133.40M | $149.40M | $101.80M | $145.70M | $40.70M | $92.60M |
| Free cash flow | $545.80M | $1.01B | $1.29B | $348.60M | $1.14B | $927.40M | $778.20M | $492.00M |
| Investing cash flow | -$6.10B | -$45.80M | -$431.90M | -$288.10M | -$117.00M | -$484.50M | -$55.80M | -$821.90M |
| Financing cash flow | $4.30B | -$426.70M | -$538.80M | -$77.20M | -$1.15B | -$349.20M | -$680.40M | -$391.30M |
| Depreciation & amortization | $69.20M | $56.50M | $55.90M | $55.70M | $54.00M | $51.70M | $48.40M | $46.50M |
| Stock-based compensation | $174.40M | $170.20M | $166.40M | $157.60M | $194.90M | $167.30M | $166.10M | $167.80M |
| Share buybacks | $126.70M | $469.50M | $336.90M | $128.40M | $1.07B | $391.80M | $426.10M | $417.90M |
Free plan shows the latest 8 periods; Pro shows all 71 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.